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Background Chronic obstructive pulmonary disease (COPD) is
set to become the third most frequent cause of death and also
the third largest cause of global morbidity by 2020. In China,
where the population is aging rapidly, COPD has become one of
the leading causes of disability and a large economic burden. An
epidemiological assessment of the COPD in China is required,
with a focus on the number of cases living with disease, main
determinants of the disease and time trends.
Methods. We systematically searched large Chinese bibliographic databases and English databases to identify spirometry–based
epidemiological studies of the prevalence of COPD in China diagnosed according to GOLD criteria. We estimated age– and
gender–specific prevalence of COPD using a multilevel mixed–
effect logistic regression. We also presented the time trends of
COPD between 1990 and 2010 by age, gender and setting (urban vs rural).
Findings In 1990, the prevalence of COPD ranged from 0.49%
(95% CI = 0.29–0.85) in <20 years group to 20.95% (95%
CI = 14.04–27.04) in> = 80 years group, and the crude prevalence for China was 2.70% (95% CI = 1.86–3.51). In 2010, the
prevalence in <20 years was 0.55% (95% CI = 0.37–1.04) and
in> = 80 years was 22.89% (95% CI = 18.13–28.96), with the
crude prevalence for China of 3.84% (95% CI = 3.30–4.77). The
COPD prevalence in males was about two–fold higher than in
females, and it increased with increasing age. Between 1990–
2010, the total number of Chinese people living with COPD increased by 66.73%, from 30.90 million (95% CI = 21.28–40.02)
in 1990 to 51.52 million (95% CI = 44.26–63.93) in 2010. This
increase was most striking in middle age, and greater in females
than in males from 30 years up to 64 years. Our estimates, which
used an independent approach to acquiring data and development of analytical methods, and were based on a more complete
data set, are remarkably similar to those produced recently by
the GBD 2013 collaboration, differing by only about 5% in the
estimated number of COPD cases in 1990 and by 1% in 2010.
Conclusions COPD is a highly prevalent disease in China and
its importance is growing steadily. The number of people living
with COPD has increased substantially between 1990 and 2010.
COPD is more frequent in males and in rural areas. Optimised
primary and secondary prevention and treatment is urgently
needed to counter this growing trend. Improved epidemiological studies will be required to assist development of more effective strategies of prevention and treatment of COPD in China in
the next decade and beyond.
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Chronic obstructive pulmonary disease (COPD), characterized by progressive airflow limitation that is
not fully reversible, is a major cause of chronic morbidity and mortality. It also carries a substantial financial burden on the society [1–4]. It is estimated that COPD was the sixth most frequent cause of death
worldwide in 1990, and will become the third by 2020 [5,6]. Within the same time frame, COPD is also
projected to become the third largest cause of global morbidity [5,7]. Cigarette smoking is the major risk
factor for COPD, and others include occupational exposures, air pollution, airway hyper–responsiveness
and asthma, while genetic predisposition may also play some role [8–11]. The startling spread of this
global health epidemic is occurring as a result of the continuous exposure to COPD risk factors and the
general aging of the global human population [5,12,13]. In China, where the population is aging very
rapidly as a result of improved living conditions, urbanization, high economic growth and family planning [14,15], COPD has become the leading cause of disability [16], resulting in a very large economic
burden [17–19]. Furthermore, the Chinese population is also at high risk of developing respiratory diseases because of indoor and outdoor pollution [10,20,21]. All the aforementioned factors indicate that
COPD may present a large challenge for the Chinese health care system in the foreseeable future.
Despite growing evidence of epidemiological and economic impact, the availability of accurate disease
burden estimates for COPD in China is challenged by the fact that COPD is often underdiagnosed or misdiagnosed [1,11]. Up–to–date information about the prevalence of COPD in general population is essential to inform stakeholders and guide health services allocation [22]. However, the evidence on the prevalence of COPD in the Chinese population is quite inconsistent, probably due to variation in case
definition and diagnostic methods, or study population characteristics [20,23]. The latest Global Burden
of Disease (GBD) 2013 study revealed a prevalence of COPD of 7.3% (95% CI = 6.7%–7.9%) in Chinese
population aged 40 years and above in the year 2013 [23]. The GBD 2013 study only included studies
of high quality, but the limited number of included studies on COPD prevalence in China could have also
limited the authors' ability to address the burden across the whole country. In addition, COPD becomes
progressively more common with age, and it could also develop relatively early in life, while previous
studies in China mainly focused on middle–aged populations [24,25]. It is, therefore, worth exploring
the burden of COPD across the entire lifespan. Another feature of COPD is that its prevalence is likely
associated with the greatest socioeconomic inequality in comparison to other common diseases, as COPD
is generally believed to disproportionally affect the poor [17,22,26]. In China, difference between the urban and rural setting provides a chance to explore the influence of socioeconomic factors and we are not
aware of a systematic analysis of urban–rural differences at the national level.
Large Chinese bibliographic databases provide a considerable amount of information that should allow
studying the epidemiology of disease in China [27,28]. In addition, spirometry method – which is the
gold standard for the diagnosis of COPD [1,29] – has been widely adopted as an accurate estimate of the
true burden of COPD in more recent epidemiological studies in China. This provides an opportunity to
systematically assess the burden of COPD in China based on a standard case definition and diagnostic
method. In this study, we conducted a comprehensive systematic review, in both Chinese and English
databases, to analyze published population–based studies of COPD prevalence in China from 1990 onwards, based on spirometry as a diagnostic tool. We also presented the time trends of COPD between
1990 and 2010 by age, gender and setting (urban vs rural).

METHODS
Systematic review and data extraction
We used CNKI, WanFang, CBM and PubMed academic databases to retrieve publications on COPD prevalence in China. Parallel searches of the databases were conducted by two independent trained reviewers
(Chinese databases: XL and WC; English databse: KYC and ANP). The search was limited to studies published between 1990 and 2014 (Figure 1). The initial screening of the four databases returned 5237 results from CNKI, 6151 from the WanFang, 3205 from CBM, and 970 from PubMed, respectively. 382
studies were retained after excluding duplicates within and between databases, studies with no numerical
values, studies conducted outside mainland China, review articles, viewpoints, conference abstracts. The
process is documented in detail in Figure 1.
Further steps included obtaining full–text versions of the retained 382 articles and checking whether they
met the minimum quality criteria to be used for further analyses and modelling. Studies were subsequently excluded if they were not prospective in design, not population based, did not report spirometry data
on COPD prevalence, did not follow the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
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Figure 1. PRISMA diagram of study selection. † –The
large majority was excluded because they were
duplicate returns of the same reference under different
search terms or in different databases; the others were
excluded because they were irrelevant to the topic of
our study, provided no numerical estimates, or studied
Chinese populations outside of mainland China. * –
These are duplicate publications of the same results in
different journals.

standard of a fixed post–bronchodilator ratio of FEV1/FVC less than 0.7, did not have full text available,
or contained insufficient or inconsistent data.

Statistical analysis
In the data extraction procedure, individual studies were used to provide multiple data points which contributed to the overall data set. To take into account the sample size and the availability of different data
points from the same study, a multilevel mixed–effect logistic regression was adopted with a restricted
cubic spline [30,31]. This was then used to model the COPD prevalence as a function of age. Based on a
total of 419 data points extracted from 67 studies with spirometry–based diagnosis of COPD, the gender– and age–specific prevalence of COPD in China was estimated. We further estimated the corresponding 95% confidence intervals (CIs) by applying the semiparametric bootstrapping method [32].
The number of gender–specific COPD cases in China in a population 20 years and older in a given year
was calculated by multiplying the estimated gender–specific prevalence for each 5–year age group with
the corresponding 5–year population in the same year, available from the United Nations Population Division (UNPD). This was performed for the years 1990, 2000 and 2010. Then, the gender–specific prevalence of COPD for the population aged <20 years was calculated by dividing the aggregated number of
COPD cases observed in this age group (which was rather small) with the aggregated size of the corresponding population in this age group. This was done across the age groups 0–4, 5–9, 10–14 and 15–19
years old. The total number of people living with COPD was derived by adding together the numbers of
males and females living with COPD, and the overall COPD prevalence was calculated by dividing the
total number of COPD cases with the total size of the population in a given year. All the analyses were
conducted in R v3.3.0 (R Development Core Team; http://www.R–project.org).

RESULTS
The characteristics of the 67 retained cross–sectional studies are shown in Table S1 and Table S2 in Online Supplementary Document: the studies were typically large, published mainly in the past decade
and led by multi–disciplinary teams of specialists. Geographically, the studies covered all 31 provinces/
municipalities/autonomous regions of mainland China.
The 67 retained studies incorporated 759 461 people tested for COPD, 45 197 of whom were diagnosed
with COPD using the spirometry method. Across most of the age spectrum in adulthood (20 years and
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more), there were large sample sizes providing substantial numbers of data points, except for the very old
age (>80 years). A total of 47 studies provided the gender–specific prevalence information. Figure 2 shows
the gender–specific relationship between the COPD prevalence and age, based on all the informative data
points. Generally, the prevalence of COPD increased steadily with age in both males and females. In males,
it reached a prevalence of about 25% by the age of 80 years, and in females it was about twice less prevalent.
Based on the information from the 47 studies, the estimates of COPD prevalence for males and females in
the years 1990, 2000 and 2010 are shown in Figure 3. Across all three years, the prevalence of COPD was
consistently greater in males than in females, and the difference was most pronounced in older adults.
A total of 56 studies provided the setting–specific prevalence information. The comparison of COPD
prevalence between urban and rural dwellers in the years 1990, 2000 and 2010 is presented in Figure
4. Similar to the comparison of gender–specific prevalence, there was a marked difference in COPD prev-

Figure 2. Gender and age–specific prevalence of chronic obstructive pulmonary disease (COPD) in China based on
the information from the systematic review. The size of each bubble is proportional to the sample size, where at
younger (<20 years) and older (>80 years) groups, the regression lines are based on fewer data points

Figure 3. Chronic obstructive pulmonary disease (COPD) prevalence for males and female in the years 1990, 2000 and 2010, with
95% confidence intervals.

Figure 4. Chronic obstructive pulmonary disease (COPD) prevalence for urban and rural dwellers in the years 1990, 2000 and 2010,
with 95% confidence intervals.
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alence between urban and rural dwellers, where people in rural areas had higher COPD prevalence than
those in urban areas.

ln(odds) = −13.388 + 0.004 × year + 0.763 × gender + 0.058 × age1 + 0.022 × age2 − 0.083 × age3 +
0.026 × age4 + ui
Where:
odds = p/(1−p), p indicates the prevalence of COPD
year = calendar year
gender = 1 for males and gender = 0 for females
age1 –age4 are variables created in the process of fitting cubic splines (knots: 34.5, 49.5, 59.8, 71.7, 79.0)
ui = the study level random effect
After applying the estimates of age– and gender–specific COPD prevalence on UN Population Division's
demographic data, the prevalence of COPD in populations aged <20 years and ≥80 years were calculated.
From 1990 to 2010, the changes in the gender specific COPD prevalence across all age groups are shown
in Figure 5 and Table 1. Over the 20 years considered in this analysis, the prevalence of COPD increased

Figure 5. Estimated gender– and age–specific prevalence of chronic obstructive pulmonary disease (COPD) in
China in the years 1990, 2000 and 2010.

Table 1. Estimated gender– and age–specific prevalence of chronic obstructive pulmonary disease (COPD) in China in the years
1990 and 2010

Prevalence of COPD in 1990 (%)
Age
(years)

Male

Female

Prevalence of COPD in 2010 (%)
Overall

Male

Female

Rate of change
(%, 1990–2010)
Overall

Male Female Overall

<20

0.65 (0.38–1.14)

0.31 (0.18–0.54)

0.49 (0.29–0.85)

0.72 (0.49–1.36)

0.34 (0.23–0.65)

0.55 (0.37–1.04)

10.77

9.68

20–24

1.26 (0.83–1.86)

0.59 (0.40–0.87)

0.94 (0.62–1.38)

1.35 (1.06–2.11)

0.64 (0.50–1.02)

1.01 (0.79–1.59)

7.14

8.47

12.24
7.45

25–29

1.67 (1.15–2.33)

0.79 (0.55–1.09)

1.25 (0.86–1.73)

1.79 (1.46–2.59)

0.84 (0.69–1.25)

1.33 (1.09–1.93)

7.19

6.33

6.40

30–34

2.22 (1.56–2.93)

1.05 (0.74–1.39)

1.66 (1.17–2.19)

2.37 (2.00–3.20)

1.12 (0.95–1.53)

1.76 (1.49–2.38)

6.76

6.67

6.02

35–39

2.93 (2.09–3.79)

1.39 (0.99–1.80)

2.20 (1.57–2.84)

3.14 (2.73–4.00)

1.49 (1.31–1.93)

2.33 (2.04–2.98)

7.17

7.19

5.91

40–44

3.88 (2.71–5.01)

1.85 (1.29–2.37)

2.90 (2.03–3.75)

4.15 (3.60–5.15)

1.98 (1.75–2.48)

3.09 (2.70–3.85)

6.96

7.03

6.55

45–49

5.18 (3.60–6.53)

2.48 (1.71–3.17)

3.90 (2.71–4.94)

5.54 (4.83–6.71)

2.66 (2.35–3.26)

4.13 (3.62–5.03)

6.95

7.26

5.90

50–54

7.02 (4.92–8.75)

3.40 (2.33–4.29)

5.31 (3.70–6.65)

7.49 (6.66–8.84)

3.64 (3.26–4.30)

5.63 (5.02–6.65)

6.70

7.06

6.03

55–59

9.55 (6.71–11.92)

4.69 (3.25–5.97)

7.23 (5.06–9.08)

10.18 (8.88–11.97)

5.02 (4.41–5.98)

7.68 (6.72–9.07)

6.60

7.04

6.22

60–64

12.77 (9.00–15.64)

6.39 (4.36–7.98)

9.66 (6.74–11.91)

13.58 (11.98–15.74)

6.82 (5.99–8.06)

10.24 (9.02–11.95)

6.34

6.73

6.00

65–69

16.48 (11.69–19.91)

8.42 (5.73–10.45)

12.38 (8.66–15.09) 17.47 (15.40–19.97)

8.98 (7.83–10.52)

13.24 (11.64–15.27) 6.01

6.65

6.95

70–74

20.32 (14.30–24.44) 10.62 (7.16–13.33) 15.23 (10.56–18.62) 21.48 (18.59–24.84) 11.31 (9.65–13.47) 16.29 (14.03–19.04) 5.71

6.50

6.96

75–79

23.95 (17.27–28.67) 12.80 (8.91–15.90) 17.68 (12.57–21.49) 25.26 (22.67–28.42) 13.61 (12.02–15.65) 18.99 (16.94–21.55) 5.47

6.33

7.41

80+

29.10 (20.17–36.28) 16.38 (10.60–21.86) 20.95 (14.04–27.04) 30.80 (24.85–37.70) 17.51 (13.57–23.02) 22.89 (18.13–28.96) 5.84

6.90

9.26

41.50 43.09

42.22

Total

3.47 (2.40–4.49)

1.88 (1.28–2.47)
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slightly in both males and females, which was also indicated in the model formula, where the annual rate
of change in prevalence on a log odds scale was only 0.004. In 1990, the prevalence of COPD ranged
from 0.49% (95% CI = 0.29–0.85) in younger people aged under 20 years to 20.95% (95% CI = 14.04–
27.04) for those who were 80 years of age or older, and the overall prevalence was 2.70% (95% CI = 1.86–
3.51). In 2010, the prevalence of COPD ranged from 0.55% (95% CI = 0.37–1.04) in people aged under
20 years to 22.89% (95% CI = 18.13–28.96) in people aged 80 years and above, with the overall prevalence in the Chinese population increasing to the level of 3.84% (95% CI = 3.30–4.77). The COPD prevalence between males and females differed consistently from 1990 to 2010, where the prevalence of COPD
in males was around two–fold higher than in females, and this difference increased with increasing age.
During 1990 to 2010, the overall prevalence of COPD increased by 42.22%. The most significant increases were in younger population who were under 20 years (12.24%) and older population aged 80
years and above (9.26%). The increasing rates were similar in males and females.
The estimates of the number of people living with COPD in China are shown in Table 2 and Figure 6.
With the aging of the Chinese population during 1990–2010, the total number of Chinese people living

Table 2. Estimated numbers of people living with COPD in China in the years 1990 and 2010, and the rate of change from 1990 to
2010, by gender and age group
People living with COPD in 1990 (million)
Age
(years)

Male

Female

Overall

<20

1.50 (0.88–2.61)

0.66 (0.39–1.15)

20–24

0.83 (0.55–1.22)

0.36 (0.24–0.53)

25–29

0.86 (0.59–1.19)

30–34

People living with COPD in 2010 (million)

Rate of change (%,
1990–2010)

Male

Female

Overall

2.16 (1.28–3.77)

1.44 (0.98–2.72)

0.57 (0.39–1.09)

2.00 (1.37–3.80)

–4.00

–13.64

–7.41

1.19 (0.79–1.75)

0.85 (0.66–1.32)

0.36 (0.28–0.58)

1.21 (0.95–1.91)

2.41

0.00

1.68

0.38 (0.26–0.52)

1.23 (0.85–1.71)

0.93 (0.76–1.34)

0.41 (0.34–0.61)

1.34 (1.10–1.95)

8.14

7.89

8.94

1.00 (0.70–1.32)

0.43 (0.30–0.57)

1.42 (1.00–1.88)

1.12 (0.94–1.51)

0.50 (0.43–0.68)

1.62 (1.37–2.19)

12.00

16.28

14.08

35–39

1.36 (0.97–1.75)

0.58 (0.41–0.75)

1.94 (1.38–2.50)

1.91 (1.66–2.43)

0.87 (0.77–1.13)

2.78 (2.43–3.56)

40.44

50.00

43.30

40–44

1.28 (0.90–1.66)

0.56 (0.39–0.72)

1.85 (1.29–2.38)

2.60 (2.26–3.22)

1.17 (1.04–1.47)

3.77 (3.29–4.70)

103.13 108.93

103.78

45–49

1.34 (0.93–1.69)

0.58 (0.40–0.74)

1.92 (1.33–2.43)

2.68 (2.33–3.24)

1.23 (1.08–1.50)

3.90 (3.42–4.74)

100.00 112.07

103.13

50–54

1.69 (1.19–2.11)

0.73 (0.50–0.92)

2.42 (1.69–3.03)

3.13 (2.79–3.70)

1.42 (1.27–1.67)

4.55 (4.06–5.37)

85.21

94.52

88.02

55–59

2.08 (1.46–2.60)

0.93 (0.65–1.19)

3.01 (2.11–3.78)

4.24 (3.70–4.98)

1.96 (1.72–2.33)

6.19 (5.42–7.31)

103.85 110.75

105.65

60–64

2.21 (1.56–2.71)

1.05 (0.72–1.32)

3.27 (2.28–4.03)

3.80 (3.35–4.40)

1.86 (1.64–2.20)

5.66 (4.99–6.61)

71.95

77.14

73.09

65–69

2.10 (1.49–2.53)

1.11 (0.76–1.38)

3.21 (2.24–3.91)

3.42 (3.02–3.91)

1.74 (1.52–2.04)

5.16 (4.54–5.95)

62.86

56.76

60.75

70–74

1.92 (1.35–2.31)

1.11 (0.75–1.39)

3.03 (2.10–3.71)

3.25 (2.81–3.75)

1.78 (1.52–2.12)

5.03 (4.33–5.87)

69.27

60.36

66.01

75–79

1.30 (0.94–1.55)

0.89 (0.62–1.11)

2.19 (1.56–2.66)

2.54 (2.28–2.86)

1.59 (1.41–1.83)

4.14 (3.69–4.70)

95.38

78.65

89.04

80+

1.03 (0.71–1.28)

1.03 (0.67–1.38)

2.06 (1.38–2.66)

2.27 (1.83–2.78)

1.90 (1.47–2.50)

4.17 (3.30–5.27)

120.39

84.47

102.43

20.50 (14.22–26.53) 10.40 (7.06–13.67) 30.90 (21.28–40.02) 34.18 (29.37–42.16) 17.36 (14.88–21.75) 51.52 (44.26–63.93) 66.73

66.92

66.73

Total

Male Female Overall

Figure 6. Estimated numbers of people living with chronic obstructive pulmonary disease
(COPD) in China by year and age group.
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with COPD increased by 66.73%, from 30.90 (95% CI = 21.28–40.02) million in 1990 to 51.52 (95%
CI = 44.26–63.93) million in 2010. Throughout this period, the number of COPD cases decreased by
7.41% in younger people aged under 20 years. The most significant increases were in those who were
middle–aged (40–49 years and 55–59 years) and at older ages (80 years and above), with rates of change
in the absolute number of cases in those age–groups above 100%. This increase was greater in females
than in males from 30 years up to 64 years. In 2010, around two–thirds (66.34%) of the people living
with COPD were males in China.

DISCUSSION
In this study, by systematically reviewing all published evidence of COPD prevalence databased on spirometry, and applying strict inclusion and exclusion criteria, we presented comprehensive and data–driven estimates of the COPD prevalence in China across the entire age range, and the differences between
males and females, and urban and rural dwellers in China. As suggested by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), a fixed post–bronchodilator ratio of FEV1/FVC less than 0.7 was
used as the primary indicator of COPD diagnosis in our study [1]. In the present study, we estimated a national GOLD–defined COPD prevalence of 2.70% in 1990 and 3.84% in 2010, corresponding to 30.90
million and 51.52 million people living with COPD in 1990 and 2010 respectively. Our estimate for the
year 2010 was similar to the estimate presented in the GBD 2013 study, which reported 32.44 million of
cases in 1990 and 54.79 million of cases in 2013 [23]. Given that the estimates presented in GBD 2013
study were based on a limited number of studies that were mostly published after 2000, any differences in
compared COPD number of cases for the year 1990 between these two studies – amounting to 1.54 million (or about 5% difference) – may be explained through this lack of data in the GBD 2013 study. Our
estimate in 2010 is relevant to a point in time 3 years earlier than the GBD 2013 estimate, but based on
our time trends we would expect our estimate for 2013 to be nearly identical to the GBD estimate, ie, just
over 54 million cases (with difference of about 1%). In comparison with the results of the GBD 2013 study,
where a slight decrease of a standardized COPD prevalence was reported between 1990 and 2013 (from
3.7% to 3.6% overall prevalence in the population), our study observed an overall increase trend of COPD
prevalence during the two decades between 1990 to 2010 – from 2.70% to 3.84%. Our estimates were
much in line with the increasing trend of COPD prevalence globally and in the Western Pacific region
[4,11]. Further analysis from an epidemiological perspective will remain to be required to explore the temporal distribution of COPD prevalence in China. The detailed and systematic estimates of COPD prevalence and the number of cases in this study constitute the best currently available basis for policymaking,
planning, and allocation of health and welfare resources related to the burden of COPD in China. The
strength of this study arises from several measures that we took to derive the estimates. First, we did a comprehensive systematic review and thus included all available studies. Second, of all the measurement methods, we chose spirometry method as the diagnosis criteria, which served to avoid potential bias arising
from the variation of measurement tools. Third, the estimate of prevalence was based on study points that
came from many different locations China, which should ensure representativeness for the whole nation.
In view of the relation between COPD prevalence and age, our study confirms that COPD is a progressive and degenerative disease [11,33]. By estimating the prevalence of COPD in the Chinese population
over the full age–span, we enabled a public health approach to prevention and treatment of COPD in
younger population. It was important to note that COPD can also exist in early life, as suggested by previous studies [24,25]. Younger populations should therefore not be excluded from COPD screening programs. In our study, although the number of COPD people in <20 years decreased slightly during 1990
to 2010, the prevalence rate kept increase. Early diagnosis is very important, and disease–modifying therapies that can delay onset could have considerable potential for reducing age–specific prevalence [34].
As expected, the prevalence in males in China was much higher than in females. The excess was most
likely to be explained by historic patterns of smoking and occupational exposures in Chinese men
[4,20,35]. From a physiological perspective, it is also widely hypothesized that women are more vulnerable to the lung–damaging effects of cigarette smoking and biomass fuels, and more prone to develop
COPD than men when they are at the same level of hazard exposure [35–37]. Our study showed a slightly higher increase of COPD prevalence and of the number of affected individuals in females than in males
during 1990 and 2010. Based on this trend, it should be expected that prevalence of COPD in Chinese
women is set to rise in the coming years, partly because of a markedly increasing rate of cigarette smoking in Chinese women [38,39].
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The prevalence of COPD was consistently higher in rural areas than in urban areas in our study. This was
in contrast with the global estimates, which show that COPD is more frequent in urban areas [4,40]. The
possible explanation is the variation in classification of rural and urban settings across the world. In China, rural areas are generally those with less (or lower–quality) health resources and worse health outcomes
in comparison to urban areas [41–44]. This urban–rural disparity of COPD prevalence may be associated with higher smoking rates, but also with prevalent indoor air pollution resulting from the burning
of wood and other biomass fuels in rural populations [10,26,45]. In addition, lower socioeconomic status, lower health resources quality, and worse quality of cigarettes may also have contributed [20,21,26].
A striking increase of 66.73% in the absolute number of estimated COPD cases between 1990 and 2010
in China was indicated by our analysis. This increase was most prominent in middle–aged and older
populations. The primary drivers of this increase were longer life expectancy in China, which led to an
increase of the number of individuals in older age groups, and continuous exposure to risk factors, which
led to an increase in prevalence among the middle–aged. The estimated number of 51.52 million people
living with COPD in China in 2010 represents a very large burden for both China and the world, where
an estimated number of 328 million people have COPD [46,47]. With the current trends of ageing in
China [14,15], the numbers of individuals affected with COPD will continue to increase, particularly in
older population. Elderly with medical care needs will constitute a burden on the health care system, and
support for family caregivers may also be needed [14,44]. In young and middle–aged populations, the
limitations in their ability to work and their overall mobility may not only lead to a reduced quality of
life, but also bring an economic challenge to both individuals and the society [18–20]. Even among the
affected individuals who only have mild symptoms, the effects of COPD may result in impaired quality
of life. These effects might be profound in many poor settings, where continuous exposure to risk factors
could accelerate the progress of the disease process [48,49].
Our study also had several potential shortcomings. Significant heterogeneity was seen between all of our
included studies. This is not surprising, given that China is a diverse country with highly varied culture,
levels of development and demographic characteristics. Although only studies that adopted the spirometry method and the GOLD criterion were included, in order to reduce the methodological variability,
heterogeneity may still exist because of the differences among investigators in operating protocols, levels
of training, adherence to guidelines and variations in implementation of the guidelines. Another possible
cause for concern is that the results of meta–regression only took into account a limited set of covariates
(ie, gender, age and urbanicity) because these were the only covariates that were broadly available. The
scarcity of studies adopting unified definition of other covariates limited our ability to explore more possible effects. Our estimates, therefore, do not take into account the role of special sub–groups exposed to
risk factors, such as smokers, household members who are exposed to biomass fuels used for home heating and cooking, workers with occupational exposures to dust, and people with tuberculosis. This is a
shortcoming that needs to be addressed in future epidemiological studies of COPD in China. In addition,
the estimates of prevalence in younger and older age groups were clearly less certain due to scarce data
and require further refinement. Finally, although GOLD criteria are widely accepted as a diagnostic tool
for COPD, they are prone to false–negative results among younger and false–positive among older adults,
which should be taken into account [1,26]. We were also unable to account for the severity of COPD,
particularly to characterise the burden of the early–stage COPD.
A growing amount of evidence suggests that ambient air pollution is a risk factor for COPD [10,50]. This
hypothesis may be of particular interest in future COPD epidemiology studies in China, where a dramatic increase in emissions of ambient air pollutants has become a large societal concern [51]. Concern is
often focused on observed air pollution levels in very large cities, but our analysis didn't find support for
COPD prevalence being a larger problem in urban as opposed to rural areas.
Our work has implications in both the academic and public health areas. Epidemiological studies that
are typically available in China on COPD could be designed better, with standardized diagnostic criteria
and much better presentation of results, taking into account different covariates. Present gaps would ideally be filled by a national disease surveillance system, but this would need considerable and sustainable
funding and training. Perhaps a more realistic approach would include high–quality epidemiology studies in large samples, such as Kadoorie study – which provided a large portion of all the data available for
our study in terms of sample size [52,53]. Adopting standardized measures of COPD, with accurate assessments of the stage and severity of COPD, effectiveness of treatment and clear definition of study population sub–groups in relation to their risk exposure would all help. Currently, most people with COPD
can only receive a diagnosis in the late stage of disease when symptoms are rather obvious [18]. Although
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COPD is not a fully reversible disease, the benefits of earlier diagnosis and treatment have been well established [11,18]. Efforts should be taken to improve the quality and availability of health care resources
to address COPD both from the point of prevention, diagnosis and treatment, especially in rural areas
where the rates of COPD prevalence are higher. In the meanwhile, the importance of primary prevention
should also be addressed, especially in primary care settings. Health education should focus on targeted
populations based on the existing evidence [21]. Advocated measures include implementation of tobacco–free policies, adequate treatment of asthma and comprehensive strategies on reducing indoor pollution. [11,18,21].

CONCLUSIONS
In conclusion, results from this study have shown that COPD is a highly prevalent disease in China and
its importance is growing steadily. The number of people living with COPD has increased substantially
and nearly doubled between 1990 and 2010. COPD is more frequent in males and in rural areas. Optimal intervention delivery – both in primary and secondary prevention and treatment – is urgently needed to counter this growing trend. Improved epidemiological studies will be required to assist development
of more effective strategies of prevention and treatment of COPD in China in the next decade and beyond.
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